For Healthcare Providers

Right treatment. Right time. Right place.

GammaTile Therapy is a Surgically Targeted Radiation Therapy 

(STaRT) that provides immediate, dose-intense treatment at completion of resection. By getting a head STaRT on fighting the tumor, resection plus GammaTile Therapy extends local

recurrence-free survival with minimal complications, reduced patient burden, and assured compliance.[1]




Outcomes & Safety

GammaTile Therapy extends local recurrence-free survival vs previous standard of care treatment.[1]

  • Significantly improves outcomes by approximately 2X
    across all tumor types in the study

    • Median time to same-site recurrence was 19.9 months, a 9.7-month improvement across all tumor types[1]



Median local control (LC) after GammaTile Therapy vs prior treatment was 12.0 vs 9.5 months for high-grade glioma (HGG) patients (HR 0.6, p = .13) and 48.8 vs 23.3 months (HR 0.24, p = .01) for meningioma patients. For the metastasis patients, the median LC has not been reached vs 5.1 months with prior treatment (HR .07, p = 0.02).[1]  The median overall survival (OS) was 12.0 months for HGG patients, 12.0 months for the brain metastasis patients, and 49.2 months for the meningioma patients.[1]


Excellent safety profile – designed to limit radiation changes in healthy tissue[1,4-8,*]

*Defined as common terminology criteria for adverse events (CTCAE), Grade 3–5 possibly or probably related to GammaTile Therapy placement occurring at any time during follow-up.

GammaTile Therapy is a safe and effective, Surgically Targeted Radiation Therapy (STaRT) for patients with recurrent brain tumors[1]
  • Extends local recurrence-free survival with minimal complications[1]

  • Reduces patient burden and preserves quality of life[1]

  • Facilitates favorable reimbursement (CMS craniotomy code ICD-10 MS-DRG 023)

Clinical efficacy, immediacy, and efficiency 

  • Enables immediate treatment at resection with no additional hospital stay 

  • Integrates into the surgical workflow for procedural ease and speed

  • Takes approximately 5 minutes to complete tile placement[1]

  • Simplifies care with 100% "built-in" compliance and no special inpatient precautions or contraindications with systemic therapies


How It Works. An Eloquent Solution.

GammaTile Therapy targets tumor cells while preserving brain tissue. Surgically guided treatment of the local radiation dose to the operative bed optimizes the therapeutic margin while minimizing complications.[1]


Structural offset of the radiation source from the brain tissue prevents harmful direct seed-to-tissue contact and enables intraoperative adjustment. 

Enhanced local control and optimized efficacy[1]

  • 50% of the therapeutic dose is delivered within the first 
    10 days after surgery, which helps prevent residual tumor cells from replicating[7]

  • 88% of the therapeutic dose is delivered within 30 days, with more than 95% of the dose delivered by 6 weeks[7]

  • A favorable depth-dose profile optimizes local
    tumor control

Bioresorbable, conformable collagen tile preserves healthy tissue 
  • Provides a structural offset of the radiation source from normal brain tissue

  • Enforces uniform radiation-source spacing, both within a single tile and between multiple tiles

  • Minimizes local hot and cold spots

  • Facilitates rapid, accurate placement to deliver a predictable radiation dose

“What I like about GammaTile is that they’re taking a radiation technology that already exists and making it safer and easier to deliver…Should be equally effective and faster to implant after tumor surgery…[It’s] better for patients (less anesthesia time) and safer for the staff (less exposure in the operating room).”

  Dr Helen Shih  

Radiation Oncologist, Massachusetts General Hospital


GammaTile Therapy Webinars

Watch an in-depth educational webinar about GammaTile Therapy, presented by world-renowned neurosurgeon, Dr Joseph Zabramski and hosted by The Musella Foundation. Content includes background, safety and efficacy, surgical placement, a case study, and clinical trial information. Watch here

This American Brain Tumor Association patient webinar provides a detailed overview of surgically implanted brain tumor therapies, including GammaTile Surgically Targeted Radiation Therapy (STaRT).  Dr John A. Boockvar, Director of the Brain Tumor and Pituitary/Neuroendocrine Center at Lenox Hill, discusses various treatment options, highlights their differences, and provides guidance on how patients can talk with their heath team about their care plan. Watch here


Notable Clinical Publications & Awards

Journal of Neurosurgery Publication
Resection and permanent intracranial brachytherapy using modular, biocompatible cesium-131 implants: results in 20 recurrent, previously irradiated meningiomas. David G. Brachman, MD, Emad Youssef, MD, Christopher J. Dardis, MD, Nader Sanai, MD, Joseph M. Zabramski, MD, Kris A. Smith, MD, Andrew S. Little, MD, Andrew G. Shetter, MD, Theresa Thomas, MS, Heyoung L. McBride, MD, MS, Stephen Sorensen, PhD, Robert F. Spetzler, MD, and Peter Nakaji, MDl, in the Journal of Neurosurgery. 2018:1-10. doi:10.3171/2018.7.jns18656

AANS Annual Meeting Abstract
Rosenblum-Mahaley Clinical Research Award winner for best abstract in field of neuro-oncology for
 Surgically targeted radiation therapy: a prospective trial in 79 recurrent, previously irradiated intracranial neoplasms on a prospective clinical trial. AANS Annual Meeting 2019

ABS Annual Meeting Abstract
Judith Stitt Best Abstract Award winner for
Surgically targeted radiation therapy: safety profile of collagen tile brachytherapy in 79 recurrent, previously irradiated intracranial neoplasms on a prospective clinical trial. ABS Annual Meeting 2019

SNO Annual Meeting Abstract

RTHP-32. First experience with gamma tile permanent implants for recurrent brain tumors. Clara Ferreira, Parham Alaei, Clark Chen, Margaret Reynolds, David Sterling, Kathryn Dusenbery, Neuro-Oncology. Volume 21, Issue Supplement_6, November 2019, Page vi216, doi:10.1093/neuonc/noz175.903


  1. Nakaji P, Youssef E, Dardis C, Smith K, Pinnaduwage D, Brachman D. Surgically targeted radiation therapy: a prospective trial in 79 recurrent, previously irradiated intracranial neoplasms. Poster presented at: 2019 AANS Annual Scientific Meeting; April 2019; San Diego, CA.

  2. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. Euro J Cancer. 2012;48:2192-2202. 

  3. Shi W, Bryan MS, Gilbert MR, et al. Investigating the effect of reirradiation or systemic therapy in patients with glioblastoma after tumor progression: a secondary analysis of NRG oncology/Radiation Therapy Oncology Group Trial 0525. Int J Radiation Oncol Biol Phys. 2018;100(1):38-44. 

  4. Combs SE, Debus J, Schulz-Ertner D. Radiotheraputic alternatives for previously irradiated recurrent gliomas. BMC Cancer. 2007;7:167. 

  5. Wernicke AG, Smith AW, Taube S, et al. Cesium-131 brachytherapy for recurrent brain metastases: durable salvage treatment for previously irradiated metastatic disease. J Neurosurg. 2017;126(4):1212-1219. 

  6. Magill ST, Lau D, Raleigh DR, Sneed PK, Fogh SE, McDermott MW. Surgical resection and interstitial iodine-125 brachytherapy for high-grade meningiomas: a 25-year series. Neurosurgery. 2017;80(3):409-416. 

  7. Armpilia CI, Dale RG, Coles IP, Jones B, Antipas V. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants.
    Int J Radiat Oncol Biol Phys. 2003;55(2):378-385. 

  8. Chiu-Tsao ST, Napoli JJ, Davis SD, et al. Dosimetry for 131Cs and 125I seeds in solid water phantom using radiochromic EBT film. Appl Radiat Isot. 2014;92:102-114. 



GammaTile Therapy is indicated to deliver radiation therapy for patients with newly diagnosed malignant and intracranial neoplasms and recurrent intracranial neoplasms. For full safety information, refer to the instructions for use. 
Download the Instructions For Use here


GammaTile Therapy is intended to deliver radiation therapy in patients with newly diagnosed malignant brain tumors and recurrent brain tumors. The potential for, and symptoms of, adverse events related to radiation exposure vary depending on the radiosensitivity of the exposed tissue, the amount of radiation delivered, and the placement of GammaTile(s). Serious side effects related to GammaTile Therapy are rare, and may include radiation brain changes including necrosis. GammaTile Therapy should not be used for patients with known history of hypersensitivity to bovine-derived materials. Possible complications can occur with any neurosurgical procedure, including cerebrospinal fluid leaks, infection, delayed hemorrhage, and adhesion formation.

  • Twitter
  • LinkedIn
  • Facebook
  • YouTube

©2020 GT Medical Technologies, Inc. I All rights reserved | Privacy Policy | Terms of Use